09:48 AM EST - Medicenna Therapeutics Corp. : Today announced the first patient dosed in the combination arm of the Phase 1/2 ABILITY (ABeta-only IL-2 ImmunoTherapY) study evaluating MDNA11, a long-acting, “beta-enhanced not-alpha” interleukin-2 (IL-2) super-agonist, with KEYTRUDA® (pembrolizumab). The combination portion of the study is designed to evaluate the potential for a synergistic effect of MDNA11 with KEYTRUDA® in patients with advanced solid tumors. Medicenna Therapeutics Corp.
shares T.MDNA are trading down $0.01 at $0.66.
